ALLEGAN, Mich., Aug. 9, 2012 - Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for clobetasol propionate shampoo, 0.05%, the generic equivalent of Clobex® Shampoo. Perrigo will commence shipment of the product immediately.
Clobetasol propionate shampoo, 0.05%, is indicated for the treatment of moderate to severe scalp psoriasis. Brand and Generic annual sales were approximately $57 million, as measured by Wolters Kluwer Health.
Perrigo's Chairman, President and CEO Joseph C. Papa stated, "This is another example of our Rx team's commitment to launching difficult to manufacture extended topical products. We are excited to market this product and are dedicated to making quality healthcare more affordable."
PR Newswire